Centessa Pharmaceuticals PLC
CNTA16.730USD
-0.080-0.48%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
2.23BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Centessa Pharmaceuticals PLC Unternehmen
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Unternehmensinformationen
BörsenkürzelCNTA
Name des UnternehmensCentessa Pharmaceuticals PLC
IPO-datumMay 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
Anzahl der mitarbeiter77
WertpapierartDepository Receipt
GeschäftsjahresendeMay 28
Addresse3rd Floor
StadtALTRINCHAM
BörseNASDAQ Global Select Consolidated
LandUnited Kingdom
PostleitzahlWA14 2DT
Telefon447391789784
Websitehttps://www.centessa.com/
BörsenkürzelCNTA
IPO-datumMay 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen Anderson
Ms. Karen Anderson
Chief People Officer
Chief People Officer
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 2
Aktualisiert: Wed, Jul 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Medicxi Ventures (UK) LLP
14.94%
Index Ventures SA
7.46%
General Atlantic LLC
7.25%
Adage Capital Management, L.P.
5.20%
Janus Henderson Investors
4.43%
Other
60.72%
Aktionäre
Aktionäre
Anteil
Medicxi Ventures (UK) LLP
14.94%
Index Ventures SA
7.46%
General Atlantic LLC
7.25%
Adage Capital Management, L.P.
5.20%
Janus Henderson Investors
4.43%
Other
60.72%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
23.53%
Venture Capital
23.05%
Investment Advisor
19.40%
Investment Advisor/Hedge Fund
15.34%
Private Equity
10.46%
Research Firm
2.54%
Individual Investor
0.50%
Endowment Fund
0.06%
Other
5.12%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
220
133.64M
100.03%
-11.01M
2025Q1
222
135.75M
101.62%
-10.84M
2024Q4
187
130.97M
99.33%
-6.00M
2024Q3
166
123.88M
97.57%
+8.26M
2024Q2
145
101.97M
89.71%
-3.69M
2024Q1
140
90.07M
89.09%
-8.60M
2023Q4
126
85.94M
86.60%
-9.82M
2023Q3
125
84.37M
86.02%
-11.03M
2023Q2
135
82.21M
85.98%
-8.96M
2023Q1
131
78.75M
82.92%
-8.68M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Medicxi Ventures (UK) LLP
19.96M
14.94%
--
--
Apr 24, 2025
Index Ventures SA
9.96M
7.46%
--
--
Apr 24, 2025
General Atlantic LLC
9.68M
7.25%
--
--
Apr 24, 2025
Adage Capital Management, L.P.
6.95M
5.2%
+1.83M
+35.85%
Mar 31, 2025
Janus Henderson Investors
5.92M
4.43%
+1.01M
+20.63%
Mar 31, 2025
T. Rowe Price Associates, Inc.
5.34M
4%
-22.05K
-0.41%
Mar 31, 2025
First Light Asset Management, LLC
4.87M
3.65%
-931.06K
-16.04%
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.33M
3.24%
+835.61K
+23.88%
Mar 31, 2025
Avoro Capital Advisors LLC
4.05M
3.03%
+4.05M
--
Mar 31, 2025
VV Manager LLC
3.93M
2.95%
--
--
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
SPDR S&P International Small Cap ETF
0.09%
iShares Biotechnology ETF
0.07%
T Rowe Price Small-Mid Cap ETF
0.05%
Fidelity Nasdaq Composite Index ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.98%
ProShares Ultra Nasdaq Biotechnology
Anteil0.14%
Invesco Nasdaq Biotechnology ETF
Anteil0.14%
SPDR S&P International Small Cap ETF
Anteil0.09%
iShares Biotechnology ETF
Anteil0.07%
T Rowe Price Small-Mid Cap ETF
Anteil0.05%
Fidelity Nasdaq Composite Index ETF
Anteil0%
First Trust IPOX Europe Equity Opportunities ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
